Inclisiran

Evidence Level: L5 Predicted Indications: 50

Quick Overview

Item Value
Drug Name Inclisiran
DrugBank ID DB14901
Brand Names (EU) Leqvio
Evidence Level L5
Predicted Indications 50
Top Prediction Score 99.93%

Approved Indication (EMA)

Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 potassium deficiency disease 99.93% DL
2 esophageal disease 99.87% DL
3 atypical coarctation of aorta 99.86% DL
4 migraine disorder 99.83% DL
5 non-syndromic esophageal malformation 99.83% DL
6 migraine with brainstem aura 99.78% DL
7 migraine with or without aura, susceptibility to 99.78% DL
8 aortic malformation 99.76% DL
9 esophageal ulcer 99.73% DL
10 Raynaud disease 99.73% DL
11 peptic esophagitis 99.68% DL
12 cauda equina syndrome 99.67% DL
13 gastrin secretion abnormality 99.65% DL
14 ulerythema ophryogenesis 99.64% DL
15 irritable bowel syndrome 99.59% DL
16 atrophoderma vermiculata 99.53% DL
17 peptic ulcer disease 99.48% DL
18 esophageal diverticulosis 99.48% DL
19 phaeochromocytoma 99.48% DL
20 dyskinesia of esophagus 99.47% DL

Showing top 20 of 50 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.